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Abstract
Preeclampsia is a potentially fatal pregnancy disorder affecting millions of women around the
globe. Dysregulation in gene and protein expression within key biological pathways control-
ling angiogenesis has been implicated in the development of preeclampsia. Altered CpG
methylation, a type of epimutation, may underlie this pathway dysregulation. In the present
study, placental tissue from preeclamptic cases and normotensive controls was analyzed for
genome-wide differential CpGmethylation and concomitant changes in gene expression. A
set of 123 genes, representing 19.9% of all genes with altered CpGmethylation, was associ-
ated with functional changes in transcript levels. Underscoring the complex relationships
between CpGmethylation and gene expression, here hypermethylation was never associ-
ated with gene silencing, nor was hypomethylation always associated with gene activation.
Moreover, the genomic region of the CpGmark was important in predicting the relationship
between CpGmethylation and gene expression. The 123 genes were enriched for their
involvement in the transforming growth factor beta (TGF-β) signaling pathway, a known regu-
lator of placental trophoblast invasion and migration. This is the first study to identify CpG
hypomethylation as an activator of TGF-β-associated gene expression in the preeclamptic
placenta. The results suggest functional epimutations are associated with preeclampsia dis-
ease status and the identified genes may represent novel biomarkers of disease.
Introduction
Across the globe preeclampsia is associated with the deaths of ~76,000 women and ~500,000
fetuses each year and impacts 5–8% of pregnancies in the United States alone [1]. Character-
ized by maternal hypertension and proteinuria that can progress to organ failure, seizures, and
maternal death, preeclampsia presently has no viable treatment or prevention options [2]. A
precise etiology of preeclampsia is unknown but is linked to impaired vascular development/
angiogenesis of the placenta, or “poor placentation,” hypothesized to be the primary
PLOSONE | DOI:10.1371/journal.pone.0141294 October 28, 2015 1 / 14
OPEN ACCESS
Citation: Martin E, Ray PD, Smeester L, Grace MR,
Boggess K, Fry RC (2015) Epigenetics and
Preeclampsia: Defining Functional Epimutations in
the Preeclamptic Placenta Related to the TGF-β
Pathway. PLoS ONE 10(10): e0141294. doi:10.1371/
journal.pone.0141294
Editor: Robert Feil, CNRS, FRANCE
Received: June 30, 2015
Accepted: October 7, 2015
Published: October 28, 2015
Copyright: © 2015 Martin et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All gene expression
and CpG methylation data are available through
Gene Expression Omnibus (GSE73377). All other
data are in the paper and its Supporting Information
files.
Funding: This research was supported by grants
from the National Institutes of Health (http://www.nih.
gov): R01 ES019315, P42 ES005948, T32
ES007126 and T32 ES007018. The funders of this
study had no role in the study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
pathological mechanism underlying the disease phenotype [3]. The causal factors for poor pla-
centation are presently unknown and likely multi-factorial in nature [2].
A possible etiologic factor in preeclampsia is an imbalance between angiogenic and antian-
giogenic growth factors. Angiogenic growth factors such as vascular endothelial growth factor
(VEGF) and placental growth factor (PLGF) are required for invasion of the spiral artery and
proper placentation [2]. Inhibitors of VEGF, such as soluble Fms-related tyrosine kinase 1
(sFLT-1), have been implicated in the etiology of preeclampsia [2]. Additionally, sFLT1 is the
best studied of these growth factors and has been proposed for use as a potential clinical bio-
marker of preeclampsia as it is highly expressed in the serum of women with preeclampsia [4],
particularly at early gestational ages [5]. By binding VEGF and PLGF, sFLT-1 is thought to cre-
ate an anti-angiogenic environment preventing proper invasion of the maternal spiral arteries
[6]. Still, it is unclear why women who develop preeclampsia have higher levels of sFLT-1, and
at the present time it is not used in the clinical setting [7]. These data highlight a gap in knowl-
edge of the contribution of specific genes that underlie preeclampsia.
Epimutations, or epigenetic modifications such as DNA methylation, are known drivers of
molecular changes to gene and protein expression levels [8]. Additionally, epimutations (spe-
cifically, alterations CpG methylation) can be induced by environmental factors [9]. Genome-
wide hypomethylation in preeclampsia has been previously observed [10,11]. As CpG methyla-
tion can directly influence the expression of genes and subsequently proteins, it has the poten-
tial to be a major contributor to disease.
The relationship between specific genes with altered CpG methylation in the preeclamptic
placenta and altered functional changes in transcript level is understudied. Prior studies have
examined differentially methylated genes in preeclampsia, and have compared changes in
genes with differential CpG methylation in genes to publicly available gene expression data
[11–15] but only one has simultaneously assessed both genome-wide DNA methylation levels
and genome-wide mRNA transcripts in the same samples [10]. To begin to fill this knowledge
gap, we analyzed relationships between changes in CpG methylation in placental tissue from
women with preeclampsia compared to controls, and the associated functional changes in gene
expression levels. Transcription factor binding site analysis was used to identify potential key
regulators of the CpG methylation patterning in the preeclamptic placenta.
Methods
Study design and collection of placental tissue samples
A total of 36 women (17 normotensive controls and 19 preeclamptic cases) receiving obstetric
care at UNC hospitals consented to collection of placental samples at the time of birth. Subjects
gave written informed consent to being enrolled and participating in this study. Preeclamptic
subjects were identified as displaying sustained de novo hypertension (>140/90 mmHg) and
proteinuria (>300mg of protein in a 24 h urine collection or urine protein/creatinine ratio of
0.3mg/dL), developing after 20 weeks of pregnancy. For inclusion in the study, subjects had to
have either blood pressure>160/110 mmHg, severe neurologic complications, or lab abnor-
malities consistent with HELLP (hemolysis, elevated liver enzymes, low platelet count) in addi-
tion to being identified as having preeclampsia syndrome as defined by the American Congress
of Obstetricians and Gynecologists. Women with confounding conditions such as pre-diabetes,
diabetes, and gestational diabetes were excluded from the study. A full-thickness placental
biopsy was obtained after delivery, avoiding the periphery and areas of obvious infarction,
flash frozen in liquid nitrogen, and subsequently stored at -70°C until analysis. This research
was approved by the Institutional Review Board at the University of North Carolina (#11–
2054).
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CpGmethylation and gene expression analysis
A 0.2 g subsection of placental tissue was cut from each frozen biopsy on dry ice, washed briefly
in sterile 1X PBS to remove any residual blood, and homogenized in Buffer RLT with B-mer-
captoethanol (Qiagen, Valencia CA). DNA and RNA sequences greater than 18 nucleotides in
length were collected using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, Valencia
CA) according to manufacturer’s instructions. CpG methylation was assessed using the Illu-
mina HumanMethylation450 BeadChip array (Illumina, Inc., San Diego, CA). This platform
assesses the DNA methylation levels of 486,428 individual probes at single nucleotide resolu-
tion. Isolated DNA was first bisulfite-converted using the EZ DNAmethylation kit (Zymo
Research, Irvine, CA) and converted DNA was then hybridized onto the array. The DNA
methylation data were collected at Expression Analysis, Inc. (Durham, NC; www.
expressionanalysis.com). Methylation levels were calculated and expressed as β values (β =
intensity of the methylated allele (M) / (intensity of the unmethylated allele (U) + intensity of
the methylated allele (M) + 100). RNA abundance was analyzed using the Affymetrix Gene-
Chip1Human Gene 2.0 ST array as described previously [16]. All data are available at the
Gene Expression Omnibus (GEO) (GSE73377).
Statistical analysis
To analyze CpG methylation levels, the data were pre-processed, following the pipeline
described in Morris et al., 2014 before performing statistical analysis [17]. For the primary
analysis to identify preeclampsia-associated CpG methylation, probes that represent known
single nucleotide polymorphism (SNPs) were removed (n = 89,678) as the technology cannot
be used to distinguish between sequence-based differences and CpG methylation differences
[18]. However, to allow for cross-study comparability we also conducted a secondary analysis
to determine whether any of the SNP-associated probes showed significant differences in CpG
methylation between preeclamptic placentas and controls. To control for the quality of probes
in the analysis, probes with detection p-values> 0.01 (n = 6,298) were removed from analysis.
Data were quantile normalized to remove experimental artifacts inherent to the array. The
resulting 390,452 quantile normalized probes were assessed for differential methylation in rela-
tion to preeclampsia case status using an Analysis of Covariance (ANCOVA) model control-
ling for gestational age, maternal age, and race [7]. The ANCOVA analysis was conducted with
Partek Genomic Suite 6.4 (St Louis, Missouri). Parametric and nonparametric analyses were
conducted using SAS 9.3 (SAS Institute Inc., Cary, North Carolina) to determine the relation-
ship between demographic variables and preeclampsia status and for covariate selection. Dif-
ferential DNAmethylation levels were statistically defined as: a p-value<0.01 for associations
with case status with a false discovery rate (FDR) corrected q-value< 0.1. To determine if CpG
methylation was associated with gene expression, Pearson correlation coefficients and associ-
ated p-values were calculated with significance set at p<0.05. We also performed a comple-
mentary analysis to enable cross-study comparisons, of all genes with differential expression
between the preeclamptic and normotensive placentas. The differentially expressed genes were
identified using an Analysis of Covariance (ANCOVA) model controlling for gestational age,
maternal age, and race as detailed above. Differential gene expression was defined as: a p-value
<0.01 for associations with case status, false discovery rate (FDR) corrected q-value< 0.1, and
fold change 2 or-2.
While single nucleotide polymorphisms were removed (n = 89,678) from the primary analy-
sis, to allow for cross-study comparability we conducted a separate analysis to determine
whether any of the SNP-associated probes were likewise differentially methylated in relation-
ship to preeclampsia. Thus, all SNP-associated probes were examined for their relationship to
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preeclampsia with a total of n = 389 identified to be differentially methylated between the pre-
eclamptic and normotensive placentas (S1 Table).
Gene ontology and pathway enrichment analysis
Genes with differentially methylated CpG levels associated with case status were analyzed for
enrichment of canonical pathways using Ingenuity Pathway Analysis Software (Ingenuity Sys-
tems, Inc., Redwood City, CA). Gene networks representing homeostatic and pathological pro-
cesses were identified through enrichment analyses. Statistical significance of network
enrichment was determined as previously described [19]. P-values represent the probability of
differentially methylated genes appearing in the associated biological network at random.
String bioinformatics software was used to construct protein networks from genes determined
to be associated with the enriched canonical pathways [20].
Additionally, we set out to determine whether there was an enrichment of transcription fac-
tor binding sites among the genes with differential CpG methylation. Using the Gene2Promo-
ter module Genomatix (http://www.genomatix.de) [21], the promoter region sequences of each
of the genes within the TGF-β pathway were analyzed with the Common Transcription Factor
Analysis Module. Core similarities of 95%, and the presence of the consensus sequence in more
than 50% of the analyzed genes were required. P values, representing the likelihood of obtain-
ing an equal or greater number of sequences with a match in a randomly drawn sample of the
same size as the input sequence set, are reported.
Results
Description of the Cohort
A total of 36 women were represented in the study, including 17 normotensive and 19 pree-
clamptics. Most of the women were of African American decent representing 35.3% of normo-
tensive women and 47.4% of preeclamptic women. Most of the women were primipara (58.3%)
and most were non-smokers (92.5%) (Table 1). The median age was 28.4 among women with
preeclampsia and 28.2 among normotensive women. Of the demographic variables tested, only
gestational age differed between the two groups. Women with preeclampsia delivered signifi-
cantly earlier than normotensive women (32.8 vs 38.6 weeks, p = 0.0001) (Table 1).
Differential CpG methylation and functional changes in gene expression
levels in the preeclamptic placenta
The methylation status of 390,452 distinct CpG probes corresponding to 20,452 individual
genes was analyzed across all placentas. There were 989 differentially methylated probes
(DMP) between the preeclamptic and normotensive placentas. As more than one probe can
correspond to a single gene, these probes represented 617 differentially methylated genes
(DMGs) (Table 2, S2 Table). The majority (n = 689, 69.7%) of the DMPs displayed a difference
in CpG methylation that exceeded 5% (Δβ -0.05 or Δβ 0.05) with a maximum difference
in methylation of ~20% (Δβ = -0.198, Δβ = 0.191) (S2 Table). In terms of directionality, most
(80.7%) of the DMPs were hypomethylated in the preeclamptic placenta versus the normoten-
sive placenta while only 19.3% were hypermethylated (Table 2, S2 Table). The five most signifi-
cant DMGs that were hypermethylated in the preeclamptic placentas relative to normotensive
placentas were Protein Tyrosine Phosphatase, ReceptorType, N Polypypeptide 2 (PTPRN2, Δβ
= 0.191), Olfactory Receptor, Family 1 Subfamily I, Member 1 (OR1I1, Δβ = 0.174), Myelin Oli-
godendrocyte Glycoprotein (MOG, Δβ = 0.165), Melanoma Antigen Family B6 (MAGEB6, Δβ
= 0.151), and Relaxin Family Peptide Receptor (RXFP, Δβ = 0.149). The five most significant
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DMGs that were hypomethylated in the preeclamptic placentas relative to normotensive pla-
centas included Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 1-Like
(MTHFD1L, Δβ = -0.194), Beta- Transducin Repeat Containing (BTRC, Δβ = -0.186), Dystonin
DST (Δβ = -0.185), Melanocortin 1 Receptor (MC1R, Δβ = -0.174) and Zinc Finger, Swim-type
(ZSWIM4, Δβ = -0.173).
The 989 DMPs were matched to their corresponding genes and subsequently analyzed for
association with gene expression across all subjects. A total of 695 DMPs could be matched
between the CpG methylation and gene expression platforms. These analyses revealed 132
DMPs (n = 123 genes) with a significant (p<0.05) association between CpG methylation level
and gene expression level representing functionally-changed differentially methylated probes
(fDMPs) (S3 Table, Fig 1). This number of fDMPs/fDMGs represents a limited proportion of
the total DMPs/DMGs, 13.3% of probes and 19.9% of genes respectively. Similar to the DMPs,
the majority (86.4%) of fDMPs were hypomethylated in the placentas of preeclamptic women
versus normotensives, with only 13.6% were hypermethylated (Table 2, S3 Table). Correlation
coefficients for the relationships between CpG methylation and gene expression ranged from
−0.77 to 0.67, with 32 of the 132 DMPs displaying a higher than moderate (R0.5) correlation
(S3 Table).
Table 1. Demographic characteristics of the study subjects.
Characteristics All N (%) /Mean
(Range)
Controls(Normotensives) N (%) /Mean
(Range)
Cases(Preeclamptics) N (%) /Mean
(Range)
p-value
Subjects 36 (100.0%) 17 (47.2%) 19 (52.8%)
Race 0.196
African American 15 (41.7%) 6 (35.3%) 9 (47.3%)
Asian 1 (2.8%) 1 (5.9%) 0 (0.0%)
Caucasian 11 (30.6%) 6 (35.3%) 5 (26.3%)
Hispanic 6 (16.7%) 4 (23.5%) 2 (10.5%)
Other 3 (8.3%) 0 (0.0%) 3 (15.8%)
Parity 0.519
Primipara 21 (58.3%) 9 (52.9%) 12 (63.2%)
Multipara 15 (41.7%) 8 (47.1%) 7 (36.8%)
Smoking Status 0.548
Smoker 2 (7.5%) 1 (5.9%) 1 (5.3%)
Non-Smoker 34 (92.5%) 16 (94.1%) 18 (94.7%)
Maternal Age (years) /28.3 (19–38) /28.2 (19–38) /28.4 (19–37) 0.9809
Gestational Age
(weeks)
/35.5 (22–41) /38.6 (35–41) /32.8 (22–40) 0.0001*
* p value < .05
doi:10.1371/journal.pone.0141294.t001
Table 2. Methylation status for differentially methylated probes (DMPs) or functionally- changed dif-
ferentially methylated probes (fDMPs).
Methylation Status DMPs (n = 989) fDMPs (n = 132)
Total Probes 989 132
Hypermethylated 191 (19.3%) 18 (13.6%)
Positively Correlated (Activation) - 18 (100.0%)
Negatively Correlated (Silencing) - 0 (0.0%)
Hypomethylated 798 (80.7%) 114 (86.4%)
Positively Correlated (Silencing) - 5 (4.4%)
Negatively Correlated (Activation) - 109 (95.6%)
doi:10.1371/journal.pone.0141294.t002
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Hypermethylation is often described as a silencer of gene expression while hypomethylation
is associated with gene activation [22]. In line with this, in the placentas studied here, the
majority (95.6%) of hypomethylated probes were associated with gene activation displaying a
negative correlation between CpG methylation and expression. In contrast to this, 4.4% of the
hypomethylated probes were associated with gene silencing (Table 2, S3 Table). Genes display-
ing these relationships are shown in Fig 2, with angiotensin receptor associated protein,
AGTRAP, representative of a gene with hypomethylation and gene activation, and tubulin fold-
ing cofactor D, TBCD, representative of a gene with hypomethylation and gene silencing (Fig
2A and 2B). Surprisingly, all of the hypermethylated fDMPs were associated with gene activa-
tion, with a positive correlation between CpG methylation and expression (Table 2, S3 Table).
Representative gene LOC257358, displays this relationship of gene hypermethylation and
increased gene expression (Fig 2C).
Position-based analysis reveals a relationship between the location of
CpGmethylation and subsequent gene expression patterns
The Illumina HumanMethylation450 BeadChip array contains information detailing the geno-
mic positions of the CpG probes within each gene. These are classified into six positions: 1500
base pairs upstream of the transcription start site (TSS1500), 200 base pairs upstream of the
transcription start site (TSS200), gene body (Body), the 5’ untranslated region (5’ UTR), the 3’
untranslated region (3’ UTR), and the 1st exon (1stExon). As the position of a methyl mark
within a gene has been previously been shown to be associated with gene expression [23], we
set out to determine whether CpG position predicted functional changes in gene expression in
the placenta.
DMPs and fDMPs were not clustered in specific genomic regions, rather they were evenly
distributed across the six different regions tested (Table 3). Region-based analysis
Fig 1. The heatmap displays the relative methylation levels of the 132 DMPs across subjects.
Preeclampsia is associated with differential methylation and expression (not shown) of 132 differentially
methylated probes (DMPs) representing 123 unique genes (fDMGs). Methylation levels are z-score
normalized across rows; red indicates relatively higher levels of methylation and blue indicates relatively
lower levels of methylation.
doi:10.1371/journal.pone.0141294.g001
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demonstrated that many (44.4%) of the hypermethylated marks occurred in gene bodies. Simi-
larly, most (50%) of the hypomethylated marks also occurred within the gene bodies, with 20%
occurring within the TSS1500 (Table 3).
Table 3. Number and percent of differentially methylated probes (DMPs) or functionally-changed differentially methylated probes (fDMPs) identi-
fied based on genomic region. Hypermethylation (hyper) and hypomethylation (hypo) in relationship to preeclampsia are detailed.
Region Probes Tested (n) DMPs (% Probes Tested) fDMPs (% DMPs) Hyper fDMPs (% hyper-fDMPs) Hypo fDMPs (% hypo-fDMPs)
1st Exon 18,609 36 (0.19%) 6 (17%) 3 (17%) 3 (3%)
3'UTR 13,738 36 (0.26%) 7 (19%) 0 (0%) 7 (6%)
5'UTR 35,131 83 (0.24%) 19 (23%) 3 (17%) 16 (14%)
Body 129,162 338 (0.26%) 65 (19%) 8 (44%) 57 (50%)
TSS1500 56,943 148 (0.26%) 24 (16%) 1 (6%) 23 (20%)
TSS200 42,544 54 (0.13%) 11 (20%) 3 (17%) 8 (7%)
Unspecified 94,325 294 (0.31%) 0 0 0
Total (n) 390,452 989 (0.25%) 132 (13.3%) 18 (100%) 114 (100%)
doi:10.1371/journal.pone.0141294.t003
Fig 2. Plots of CpGmethylation levels and gene expression levels across all subjects for three
representative genes. The plots display the three observed relationships of CpGmethylation and gene
expression. For each plot, the median β value for the preeclamptic and normotensive subjects is provided.
The total number of genes (n) identified in the study that display a similar pattern as the representative genes
is detailed.
doi:10.1371/journal.pone.0141294.g002
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Relationship to previously implicated preeclampsia-associated genes
Through literature reviews we identified a total of 376 genes suspected to play a role in pre-
eclampsia (S4 Table). Of these, 25 were among the 617 DMGs representing a significant (χ2 p-
value = 0.0002) number and seven were fDMGs (S2 Table, S3 Table). Six of the seven displayed
expression changes that were consistent with what has been previously reported in the litera-
ture: angiotensin receptor associated protein (AGTRAP), collagen Type IV Alpha 2 (Col4A2),
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), krueppel-like factor 9 (KLF9), lactate
dehydrogenase A (LDHA), and solute carrier family 1 (Neutral Amino Acid Transporter),
member 5 (SLC1A5) transcripts (S3 Table). The expression of plasma membrane calcium-
transporting ATPase 4 (ATP2B4) was associated with preeclampsia, however the relationships
reported were not consistent between studies. In the present study it was found to be hypo-
methylated in preeclamptic women, as well as increased in expression (S3 Table).
The TGF-β pathway is enriched among the functionally changed DMGs
All DMPs and DMGs, both those that were only changed at the CpG methylation levels and
those that were functionally changed at the gene expression level, were analyzed for their role
in biological pathways. Interestingly, the TGF-β pathway was significantly enriched within
both the DMGs (p = 0.0005) and fDMGs (p = 0.0014) (S5 Table). The following five genes
were differentially methylated: Runt-Related Transcription Factor (RUNX2) (Δβ = -0.112),
Mitogen Activated Protein Kinase 8 (MAPK8) (Δβ = -0.076), Transforming Growth Factor- β
3 (TGFβ3) (Δβ = -0.068), Bone Morphogenic Protein 7(BMP7) (Δβ = -0.105), and Paired-like
homeodomain 2 (PITX2) (Δβ = -0.077). The following four genes were differentially methyl-
ated and differentially expressed (fDMGs): Runt-Related Transcription Factor 3(RUNX3)
(Δβ = -0.109), Mothers against decapentaplegic homolog 3 (SMAD3) (Δβ = -0.162),
proto-oncogene Ski (SKI) (Δβ = -0.120), and TGFB-induced factor homeobox 1 (TGIF1)
(Δβ = -0.078). The TGF-β-associated genes were exclusively hypomethylated with some dis-
playing concomitant increases in gene expression (Fig 3).
Analysis of enrichment for binding sites for transcription factors among the differentially
methylated genes that were associated with the TGF-β pathway was conducted. This analysis
revealed enrichment for binding sites for three transcription factors with enriched binding sites
in the sequences: Kidney-enriched Kruppel-like factor 15 (KLF15), Myeloid Zinc Finger Pro-
tein 1 (MZF1), and Kruppel-like Zinc Finger protein 219 (ZNF219) (Table 4).
Also of interest were the fDMPs associated with Tetrahydrofolate Salvage from 5,10-methe-
nyltetrahydrofolate and Folate Metabolism (S5 Table). These pathways include two genes:
Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 1-Like (MTHFD1L) and
Methylenetetrahydrofolate Dehydrogenase (NADP+ dependent) 2 (MTHFD2), both of which
were hypomethylated with increased expression (S2 Table). To noteMTHFD1L was the most
hypomethylated gene in the dataset, with 20% lower methylation in the preeclamptic placenta
relative to the normotensive placenta (S2 Table, S3 Table).
Identification of differentially expressed genes independent of changes
in methylation status
As a supplemental analysis to enable cross-study comparisons, genes with altered gene expres-
sion in the preeclamptic placenta were identified irrespective of changes to CpG methylation.
This results in the identification of 1,602 probes corresponding to 729 unique differentially
expressed genes (DEGs) (S6 Table). Comparisons to genes implicated in preeclampsia revealed
that 13 out of the 729 genes with altered expression were among the 381 genes that have been
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previously associated with preeclampsia, an insignificant number (p = 0.852) (S6 Table, S3
Table).
Relationship to previously implicated gestational age-associated genes
While the statistical model used to identify probes with significant differences in CpG methyla-
tion associated with preeclampsia corrected for gestational age of the subjects, we wanted to
ensure that the differences in CpG methylation were not simply due to differences in gesta-
tional age of the subjects. Gene expression data fromWinn et al., were compiled representing
418 genes known to have differential expression in the placenta dependent upon gestational
age [24]. The DMPs and fDMGs that were identified were compared to this list and only 15
preeclampsia-associated DMPs were identified (p = 0.112). The DMGs associated with gesta-
tional age were: Melanocortin 1 recptor (MC1R), Lactate Deyhdrogenase (LDHA), CoA
Synthase (COASY), Ras Related Protein (RAB31), Adipocyte Adhesion Molecule (ASAM),
Paired-like Homeodomain 2 (PITX2), RNA Binding Motif Single Stranded Interacting Protein
1 (RBMS1), PDZ and LIM Domain 1 (PDLIM1), Solute Carrier Family 35 (SLC35D1),Tumor
Necrosis Factor Receptor Superfamily Member 21 (TNFRS21), Dipeptidase 2 (DPEP2),
Table 4. Transcription factors with enriched binding sites among the TGF-β pathway-associated genes.
Gene Symbol Full Transcription Factor Name p-value Total # Sequences # Matched Sequences
KLF15 Kidney-enriched kruppel-like factor 15 0.001304 68 24
MZF1 Myeloid zinc finger protein 1 0.001968 41 25
ZNF219 Kruppel-like zinc finger protein 219 0.000288 73 24
doi:10.1371/journal.pone.0141294.t004
Fig 3. Protein interaction network showing the relationships between differentially methylated genes
within the TGF-β pathway. The colors represent the different lines of evidence: green represents
associations determined by literature searches, magenta represents experimentally-derived evidence, and
blue represents associations reported in databases.
doi:10.1371/journal.pone.0141294.g003
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Ciracdian Associated Receptor of Transcription (C1orf151), Von Willebrand Factor (VWF),
Ral Guanine Nucleotide Dissociation Stimulator-like 2 (RGL2), and V-ETs Avian Erythoro-
blastosis Virus E26 Oncogen Homolog (ERG). Only one of these genes, PITX2, was among the
genes belonging to the TGF-β pathway. Only five of the fDMGs were significantly associated
with gestational age (p = 0.160). These included TNFRSF21, VWF, SLC35D1, LDHA, and
PDLIM1 and none of these genes were members of the TGF-β pathway (S3 Table).
Discussion
The molecular mechanisms underlying the initiation and disruption of placental gene expres-
sion observed in preeclampsia remain largely unknown. Here we identified sites of CpG meth-
ylation altered in the preeclamptic placenta, as well as CpG methylation marks that were
directly linked to functional changes in gene expression in the preeclamptic placenta. The
majority (69.7%) of the CpG methylation changes identified in the preeclamptic placenta dis-
played greater than a 5% difference relative to normotensive subjects, a change that has been
associated with functional implications for altered gene expression [25,26]. Most of these
observed differences in CpG methylation were lower in the preeclamptic placenta relative to
the normotensive placenta supporting previously published data regarding hypomethylation of
promoters regions in the preeclamptic placenta [10,11]. In addition to the identification of
CpG methylation related to the TGF-β pathway, we identified 25 known preeclampsia-associ-
ated genes with altered CpG methylation with seven displaying functional changes in gene
expression including AGTRAP and Col4a2. AGTRAP plays a role in the angiotensin pathway
and Col4a2 is associated with early onset preeclampsia [2,7]. These data highlight that there is
a general loss of CpG methylation in the preeclamptic placenta that is significantly different
from normotensive women, and that gene expression is tied to these changes in methylation.
Interestingly, genes with altered CpG methylation and concomitant changes in gene expres-
sion level enrich for the TGF-β pathway and include: SMAD3, SKI, RUNX3, and TGIF1. For all
genes associated with the TGF- β pathway, the methylation differences between the preeclamp-
tic and normotensive placentas exceeded 5%. The TGF-β pathway showed a general hypo-
methylation with increased expression in the preeclamptic placenta. Supporting our results,
this pathway has been implicated in control of trophoblast invasion and migration. TGF-β is
elevated in the serum of preeclamptic patients and is known to inhibit the angiogenic factor
VEGF in many tissues [27–29]. In the present study SMAD3 (Δβ = -0.162) was among the top
10 most hypomethylated sites and displayed increased expression in the preeclamptic placenta.
SMAD3 is known to complex with TGF- β [30,31]. While not identified to differential CpG
methylation in the present study, an additional member of this pathway, TGF- β2, has been
proposed as a predictive biomarker for preeclampsia with elevated serum levels in women with
preeclampsia [32]. In the present study TGF- β3 was hypomethylated (Δβ = -0.068) in the pre-
eclamptic placenta which is interesting as increased expression of TGF- β3 during pregnancy
has been associated with preeclampsia [33]. This is the first study to highlight the epigenetic
regulation of the TGF-β signaling as a potential etiologic factor in preeclampsia.
Our hypothesis for gene-specific patterning of DNA methylation is the “transcription factor
occupancy” theory where binding of transcription factors can influence subsequent methyla-
tion patterning across the genome [23,34]. Interestingly, two of the three transcription factors
associated with the TGF-β pathway-associated genes have been previously associated with pre-
eclampsia. Both ZNF219 and MZF-1 have demonstrated altered expression in the decidua or
placentas of preeclamptic women [35,36]. While KLF15 has not previously been identified in
association with preeclampsia, it is a known regulator of TGF- β expression [37,38]. Taken
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together these data suggest that transcription factor binding may influence the DNAmethyla-
tion patterning related to TGF- β in the preeclamptic placenta.
It was interesting to find fDMGs that play a role in folate scavenging metabolism, including
MTHFD1L andMTHFD2, that showed hypomethylation and increased expression in the pre-
eclamptic placenta. Additionally, among all genes tested,MTHD1L displayed the greatest
degree of change in methylation, with a nearly 20% decrease in CpG methylation in the pre-
eclamptic placenta relative to the normotensive placenta. These genes have not been previously
implicated in preeclampsia or associated with preeclampsia, however, folate deficiency has
been previously tied to preeclampsia [39]. It is thought that the lack of folate may be tied to the
incorrect development of the placenta [39]. Supplementation with folate has been used with
limited success in attempts to decrease risk for preeclampsia [40,41]. Interestingly both of the
genes we identified with increased expression encode enzymes linked to the conversion, and
thus depletion, of folate to tetrahydrofolate and its downstream metabolites.
CpG methylation and gene expression correlations are typically described as being negative
where hypermethylation acts as a silencing mechanism and hypomethylation an activating
mechanism [22]. In the present study, the majority of fDMPs were negatively associated with
gene expression. There were a number of fDMPs, however, that displayed a positive association
between CpG methylation and expression. We observed that hypermethylation within the
gene body was often associated with increased gene expression as we and others have previ-
ously reported [23,34,42]. Additionally, we also observed that promoter-based hypomethyla-
tion was always associated with increased gene expression, suggesting that as previously
reported, body based and promoter based methylation have differing functional consequences
on gene expression [11,34,42]. These data suggest that measures of gene expression are critical
to determine whether CpG methylation has a functional consequence and whether it repre-
sents a silencing or activating mechanism, highlighting the complex relationship between CpG
methylation and gene expression.
While we have found CpG methylation control of key biological pathways, this study is not
without limitations. A relatively small sample size (n = 36) was available for study and BMI, a
risk factor for preeclampsia, was not available and therefore could not be accounted for. Lastly,
preeclamptic women and normotensive women differed significantly in gestational age. To
address this limitation, we included gestational age as a covariate in the analytical model as
well as compared the identified DMGs/fDMGs to a known database of genes changed in
expression associated with gestational age resulting in little overlap. Nevertheless, this study
has numerous advantages such as the utilization of placental tissue versus maternal serum,
which is key as poor placentation is highly relevant in relationship to placental toxicity.
Taken together, out study provides evidence that altered DNA methylation of the TGF-β
pathway is linked to its elevated expression in the preeclamptic placenta. These data increase
the understanding of mechanisms of transcriptional control that underlie preeclampsia and
provide new target molecules and biological pathways in the formulation of preventative and
treatment strategies.
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